HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announced its participation in a high-profile Congressional roundtable in North Carolina, focused on emerging virtual therapeutic options for opioid treatment. The event was hosted by the Breaking Barriers for Substance Use Recovery initiative and featured key stakeholders from across the healthcare and policy spectrum.

The roundtable, held with Dr. Greg Murphy, U.S. Congressman representing North Carolina's 3rd District, centered on the deployment of virtual-based opioid therapy models across the country. Dr. Murphy, Congress’ only actively practicing physician, serves on the Health Subcommittee of the Veterans Affairs Committee and is a strong advocate for innovative healthcare solutions, particularly those aimed at addressing the opioid crisis.

The invitation-only roundtable brought together thought leaders and innovators to discuss the potential of virtual therapies to overcome the stigma and geographic barriers often associated with traditional in-clinic treatment options. Nexalin’s approach to virtual therapeutic solutions, which is expected to play a significant role upon FDA clearance, was highlighted as a promising tool in the fight against opioid addiction.

“Nexalin is honored to participate in this crucial dialogue and to work alongside visionary leaders in the fight against addiction like Congressman Murphy, who has worked tirelessly to address challenges at the VA in service of our veterans,” said Mark White, CEO of Nexalin Technology. “Our mission is to provide effective, accessible treatment options that can reach those in need, regardless of their location. We believe that virtual therapeutic models, combined with our non-invasive neurostimulation technology, have the potential to revolutionize the way opioid addiction is treated across the nation, especially among veterans in rural communities. This meeting continues to build on the success of our Nexalin America division, which is aimed at expanding Nexalin’s efforts within the U.S. Government areas of interest.”

During the discussions, emphasis was placed on establishing stronger practices within the Department of Veterans Affairs (VA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to encourage the adoption of virtual-based therapies. These therapies, including Nexalin’s cutting-edge neurostimulation technology, aim to provide effective treatment options that can be accessed remotely, expanding the reach and impact of mental health care.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com